



+7.3%

Like-for-like growth

74.8%

Gross margin +50bps

20.8%

Operating margin


+10bps

€3.65Bn

Net profit


+8.8%






3







L'ORÉAL













Professional Products



Consumer Products



Luxe



Dermatological Beauty




* Like-for-like vs 2023





H1-2024 sales by region (in billion euros, like-for-like growth) Developed and emerging markets offsetting North Asia



^{*} South Asia Pacific, Middle-East, North Africa - Sub-Saharan Africa

^{**} Emerging Markets combine the Latin America and SAPMENA-SSA regions





H1-2024 sales by category Broad-based growth, led by hair care and fragrances





Profit and loss account From sales to operating profit

| (in million euros) | H1-2023 | % of sales | 2023 | % of sales | H1-2024 | % of sales | Change |
|--|----------|------------|-----------|------------|----------|------------|--------|
| Sales | 20 574.1 | 100.0% | 41 182.5 | 100.0% | 22 120.8 | 100.0% | +7.5% |
| Cost of sales | -5 291.5 | 25.7% | -10 767.0 | 26.1% | -5 568.7 | 25.2% | |
| Gross profit | 15 282.6 | 74.3% | 30 415.5 | 73.9% | 16 552.1 | 74.8% | +50bp |
| Research and innovation expenses | -622.8 | 3.0% | -1 288.9 | 3.1% | -667.3 | 3.0% | |
| Advertising and promotion expenses | -6 682.6 | 32.5% | -13 356.6 | 32.4% | -7 109.1 | 32.1% | -40bp |
| Selling, general and administrative expenses | -3 718.5 | 18.1% | -7 626.7 | 18.5% | -4 176.6 | 18.9% | +80bp |
| Operating profit | 4 258.8 | 20.7% | 8 143.3 | 19.8% | 4 599.1 | 20.8% | +10bp |





Operating margins by division (% of sales) Three divisions at record first-half highs

| | H1-2023 | 2023 | H1-2024 |
|--------------------------------------|----------|-------|----------|
| | 111-2025 | 2023 | 111-2024 |
| Professional Products | 21.2% | 21.6% | 22.1% |
| Consumer Products | 21.0% | 20.5% | 22.0% |
| Luxe | 23.2% | 22.3% | 21.9% |
| Dermatological Beauty | 28.4% | 26.0% | 28.9% |
| Total before non-allocated expenses* | 23.0% | 22.2% | 23.2% |
| Non-allocated expenses | -2.3% | -2.4% | -2.4% |
| Group | 20.7% | 19.8% | 20.8% |

^{*} Central group expenses, fundamental research expenses, free grant of shares expenses and miscellaneous items as a % of total sales





Profit and loss account From operating to net profit excluding non-recurring items

| (in million euros) | H1-2023 | 2023 | H1-2024 | % Change |
|---|-------------|-------------|-------------|----------|
| Operating profit | 4 258.8 | 8 143.3 | 4 599.1 | +8.0% |
| Financial revenues/expenses before dividends received | -45.3 | -113.4 | -131.0 | |
| Sanofi dividends | 420.9 | 420.9 | 444.5 | |
| Profit before tax and associates, excluding non-recurring items | 4 634.4 | 8 450.8 | 4 912.6 | +6.0% |
| Income tax excluding non-recurring items | -1 013.2 | -1 957.8 | -1 163.9 | |
| Net profit excluding non-recurring items of equity consolidated companies | _ | +0.2 | -0.8 | |
| Non-controlling interests | -4.6 | -6.6 | -3.3 | |
| Net profit excluding non-recurring items after non-controlling interests | 3 616.6 | 6 486.6 | 3 744.6 | |
| Earnings per share (in euros)* | 6.73 | 12.08 | 6.98 | +3.7% |
| Diluted average number of shares | 537 136 456 | 537 021 039 | 536 387 970 | |

^{*} Diluted earnings per share attributable to owners of the company, excluding non-recurring items





From net profit excluding non-recurring items to net profit

← Non-recurring items -89.0 → →



* Versus \$1-2023





Cash flow statement

(in million euros)

| | H1-2023 | 2023 | H1-2024 | % Change |
|---|----------|----------|----------|-------------|
| Net profit | 3 363.6 | 6 190.5 | 3 658.9 | |
| Depreciation, amortisation and provisions | 911.3 | 1 715.0 | 769.7 | |
| Capital gains / losses on disposals of assets, changes in deferred taxes, other | 103.4 | 94.1 | 83.3 | |
| Share of profit in associates, net of dividends received | _ | -0.2 | 2.2 | |
| Cash flow | 4 378.3 | 7 999.5 | 4 514.0 | +3.1% |
| Changes in working capital | -1 556.6 | -394.9 | -1 745.8 | |
| Investments | -724.1 | -1 488.7 | -781.1 | |
| Operating net cash flow | 2 097.5 | 6 115.9 | 1 987.1 | -5.3% |
| Dividends paid | -3 398.2 | -3 425.6 | -3 605.9 | |
| Acquisitions | -159.4 | -2 497.2 | -138.0 | |
| Lease debt repayment | -211.2 | -430.6 | -235.4 | |
| Acquisitions of treasury stock | | -503.3 | | |
| Capital increase | | 1.5 | | |
| Others | -40.2 | -157.8 | -31.8 | |
| Residual cash flow | -1 711.5 | -897.2 | -2 023.9 | |
| ORÉAL 31 July 2024 | | | | 1: |




Balance sheet (as of 30 June) A robust financial position (in billion euros)



^{*} Of which €1 895m due to financial lease debt at the end of June 2024 (IFRS 16) and of €1 854m at the end of December 2023







Gearing*

21.8% (vs 17.3%) Leverage (net debt/EBITDA**)

1.2x (vs 1.0x)

14

** Calculated over 12-month EBITDA to end of June 2024



^{*} Net debt/equity attributable to owners of the company (15.4% excluding financial lease debt)

- APPENDIX

Avertissement / Disclaimer

« Ce document ne constitue pas une offre de vente ou la sollicitation d' une offre d' achat de titres L' Oréal. Si vous souhaitez obtenir des informations plus complètes concernant L' Oréal, nous vous invitons à vous reporter aux documents publics déposés en France auprès de l' Autorité des Marchés Financiers (également disponibles en version anglaise sur notre site Internet www.loreal-finance.com). Ce document peut contenir certaines déclarations de nature prévisionnelle. Bien que la Société estime que ces déclarations reposent sur des hypothèses raisonnables à la date de publication du présent communiqué, elles sont par nature soumises à des risques et incertitudes pouvant donner lieu à un écart entre les chiffres réels et ceux indiqués ou induits dans ces déclarations.»

"This document does not constitute an offer to sell, or a solicitation of an offer to buy, L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers (which are also available in English on our Internet site: www.loreal-finance.com). This document may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements."

L'ORÉAL



16



| | Weight in H1 2024 consolidated sales | Average rate H1 2023 | Average rate H1 2024 | % Change H1 2024 vs. H1 2023 |
|-------------------|--------------------------------------|-------------------------|-------------------------|---------------------------------|
| Euro | 20.9% | _ | _ | _ |
| US Dollar (1 € =) | 24.7% | 0.925 | 0.925 | 0.0% |
| Chinese Yuan | 15.9% | 0.133 | 0.128 | -4.0% |
| Pound Sterling | 3.9% | 1.140 | 1.170 | +2.6% |
| Mexican Peso | 2.7% | 0.050 | 0.054 | +6.1% |
| Canadian Dollar | 2.4% | 0.686 | 0.681 | -0.8% |
| Brazilian Real | 2.2% | 0.182 | 0.182 | -0.2% |
| Australian Dollar | 1.7% | 0.625 | 0.609 | -2.6% |
| Russian Rouble | 1.3% | 0.012 | 0.010 | -15.2% |
| Indian Rupee | 1.3% | 0.011 | 0.011 | -1.2% |



Avertissement / Disclaimer

« Ce document ne constitue pas une offre de vente ou la sollicitation d'une offre d'achat de titres L'Oréal. Si vous souhaitez obtenir des informations plus complètes concernant L'Oréal, nous vous invitons à vous reporter aux documents publics déposés en France auprès de l'Autorité des Marchés Financiers (également disponibles en version anglaise sur notre site Internet www.loreal-finance.com). Ce document peut contenir certaines déclarations de nature prévisionnelle. Bien que la Société estime que ces déclarations reposent sur des hypothèses raisonnables à la date de publication du présent communiqué, elles sont par nature soumises à des risques et incertitudes pouvant donner lieu à un écart entre les chiffres réels et ceux indiqués ou induits dans ces déclarations.»

"This document does not constitute an offer to sell, or a solicitation of an offer to buy, L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers (which are also available in English on our Internet site: www.loreal-finance.com). This document may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements."

L'ORÉAL